Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

Literature DB >> 10379419

Metabolism of some "second"- and "fourth"-generation antidepressants: iprindole, viloxazine, bupropion, mianserin, maprotiline, trazodone, nefazodone, and venlafaxine.

S Rotzinger¹, M Bourin, Y Akimoto, R T Coutts, G B Baker.

Abstract

1. This review summarizes the major known aspects of the metabolism of second-generation (iprindole, viloxazine, bupropion, mianserin, maprotiline, and trazodone) and fourth-generation (nefazodone and venlafaxine) antidepressants. 2. Discussions about specific enzymes involved and about possible pharmacokinetic drug-drug interactions, particularly as they relate to cytochrome P450 enzymes, are provided.

Entities: Chemical

Mesh：

Substances：

Year: 1999 PMID： 10379419 DOI： 10.1023/a:1006953923305

Source DB: PubMed Journal: Cell Mol Neurobiol ISSN： 0272-4340 Impact factor: 5.046

112 in total

1. Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine.

Authors: A Metz; R I Shader
Journal: Int Clin Psychopharmacol Date: 1990-07 Impact factor: 1.659

2. Effects of trazodone and fluoxetine in the treatment of major depression: therapeutic pharmacokinetic and pharmacodynamic interactions through formation of meta-chlorophenylpiperazine.

Authors: M Maes; H Westenberg; E Vandoolaeghe; P Demedts; A Wauters; H Neels; H Y Meltzer
Journal: J Clin Psychopharmacol Date: 1997-10 Impact factor: 3.153

3. The influence of environmental and genetic factors on CYP2D6, CYP1A2 and UDP-glucuronosyltransferases in man using sparteine, caffeine, and paracetamol as probes.

Authors: K W Bock; D Schrenk; A Forster; E U Griese; K Mörike; D Brockmeier; M Eichelbaum
Journal: Pharmacogenetics Date: 1994-08

Review 4. Drug interactions with newer antidepressants: role of human cytochromes P450.

Authors: D J Greenblatt; L L von Moltke; J S Harmatz; R I Shader
Journal: J Clin Psychiatry Date: 1998 Impact factor: 4.384

5. Detection and quantitation of a ring-hydroxylated metabolite of the antidepressant drug tranylcypromine.

Authors: G B Baker; D R Hampson; R T Coutts; R G Micetich; T W Hall; T S Rao
Journal: J Neural Transm Date: 1986 Impact factor: 3.575

6. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine.

Authors: U Jeppesen; L F Gram; K Vistisen; S Loft; H E Poulsen; K Brøsen
Journal: Eur J Clin Pharmacol Date: 1996 Impact factor: 2.953

Review 7. Antidepressant drug selection: criteria and options.

Authors: S H Preskorn
Journal: J Clin Psychiatry Date: 1994-09 Impact factor: 4.384

8. The disposition of [14C]iprindole in man, dog, miniature swine, rhesus monkey and rat.

Authors: S F Sisenwine; C O Tio; H W Ruelius
Journal: Xenobiotica Date: 1979-04 Impact factor: 1.908

Review 9. Pharmacology and neurochemistry of nefazodone, a novel antidepressant drug.

Authors: D P Taylor; R B Carter; A S Eison; U L Mullins; H L Smith; J R Torrente; R N Wright; F D Yocca
Journal: J Clin Psychiatry Date: 1995 Impact factor: 4.384

10. Maprotiline metabolism appears to co-segregate with the genetically-determined CYP2D6 polymorphic hydroxylation of debrisoquine.

Authors: L Firkusny; C H Gleiter
Journal: Br J Clin Pharmacol Date: 1994-04 Impact factor: 4.335

11 in total

1. Metabolism of bupropion by baboon hepatic and placental microsomes.

Authors: Xiaoming Wang; Doaa R Abdelrahman; Valentina M Fokina; Gary D V Hankins; Mahmoud S Ahmed; Tatiana N Nanovskaya
Journal: Biochem Pharmacol Date: 2011-05-05 Impact factor: 5.858

Review 2. Clinically significant drug interactions with antidepressants in the elderly.

Authors: Edoardo Spina; Maria Gabriella Scordo
Journal: Drugs Aging Date: 2002 Impact factor: 3.923

3. Does trazodone have a role in palliating symptoms?

Authors: Mellar P Davis
Journal: Support Care Cancer Date: 2006-11-28 Impact factor: 3.603

Review 4. Pharmacotherapy for mood disorders in pregnancy: a review of pharmacokinetic changes and clinical recommendations for therapeutic drug monitoring.

Authors: Kristina M Deligiannidis; Nancy Byatt; Marlene P Freeman
Journal: J Clin Psychopharmacol Date: 2014-04 Impact factor: 3.153

5. Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach.

Authors: Paul K Kiptoo; Kalpana S Paudel; Dana C Hammell; Raghotham Reddy Pinninti; Jianhong Chen; Peter A Crooks; Audra L Stinchcomb
Journal: J Pharm Sci Date: 2009-02 Impact factor: 3.534

Review 6. Fighting insomnia and battling lethargy: the yin and yang of palliative care.

Authors: Mellar P Davis; Harold Goforth
Journal: Curr Oncol Rep Date: 2014-04 Impact factor: 5.075

7. Bupropion dose-dependently reverses nicotine withdrawal deficits in contextual fear conditioning.

Authors: George S Portugal; Thomas J Gould
Journal: Pharmacol Biochem Behav Date: 2007-08-23 Impact factor: 3.533

8. An investigation of bupropion substitution for the interoceptive stimulus effects of nicotine.

Authors: J L Wilkinson; F I Carroll; R A Bevins
Journal: J Psychopharmacol Date: 2009-03-20 Impact factor: 4.153

9. Impact of polymorphisms of cytochrome-P450 isoenzymes 2C9, 2C19 and 2D6 on plasma concentrations and clinical effects of antidepressants in a naturalistic clinical setting.

Authors: Katja Grasmäder; Petra Louise Verwohlt; Marcella Rietschel; Aleksandra Dragicevic; Matthias Müller; Christoph Hiemke; Nikolaus Freymann; Astrid Zobel; Wolfgang Maier; Marie Luise Rao
Journal: Eur J Clin Pharmacol Date: 2004-05-28 Impact factor: 2.953

10. Getting the balance right: Established and emerging therapies for major depressive disorders.

Authors: Bojana Perović; Marija Jovanović; Branislava Miljković; Sandra Vezmar
Journal: Neuropsychiatr Dis Treat Date: 2010-09-07 Impact factor: 2.570